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Abstract
Background: Multiple sclerosis (MS) is a complex, inflammatory and neurodegenerative disease of the central nervous 
system leading to long-term disability. Recent studies indicate a close association between inflammation and 
neurodegeneration in all lesions and disease stages of MS. Prolyl oligopeptidase (POP) is a proline-specific serine 
protease that cleaves several neuroactive peptides. This peptidase has been implicated in neurodegeneration, as well 
as in the modulation of the inflammatory response.
Methods: We examined plasma POP and the levels of an endogenous POP inhibitor from relapsing remitting MS 
patients and compared these with healthy controls, by monitoring the fluorescent changes due to standard 
fluorescently labelled substrate cleavage. We analysed the data in relationship to patient age and disease disability 
status.
Results: We observed a significant decrease in POP activity in plasma of relapsing remitting MS patients relative to 
healthy controls, coupled with an increase of POP endogenous inhibitor. The POP activity was also correlated with 
patient age and disability status. The lowered POP activity from plasma of MS patients could be rescued by reductants
Conclusions: The decrease in circulating POP activity measured in MS is reverted by reductants. This suggests that POP 
inactivation in MS might be a result of the oxidative conditions prevailing in the plasma of the diseased patients. 
Plasma levels of POP activity as well as those of their endogenous inhibitor are suggested as biomarkers of 
inflammation and oxidative stress in MS.
Background
Prolyl oligopeptidase (POP) is a proline-specific endo-
peptidase, highly expressed in brain, that cleaves neuro-
active peptides implicated in memory, learning and also
in neurodegeneration [1,2]. The distribution of the
enzyme across the brain indicates that POP may be
involved in the thalamocortical neurotransmission, mem-
ory and learning functions of hippocampal formation and
GABAergic regulation of voluntary movements [3-5].
POP inhibitors are neuroprotective in certain experimen-
tal settings, for instance in brain ischemia and in T-cell
activation-induced cell death [1]. Active POP increases
the aggregation rate of α-synuclein in vitro [6], and serum
levels of this activity are lower in different stages of
depression and higher in mania [7]. Furthermore, the
effect of the mood-stabilizing drugs, lithium, carbam-
azepine and valproic acid, can be reversed by POP inhibi-
tion [8]. Additionally, POP inhibitors can reverse
memory loss in rodents under several experimental con-
ditions, such as scopolamine administration [9] or brain
ischemia [10]. A POP endogenous inhibitor has been
described [11] and proposed as a regulator of POP activ-
ity in cells, tissues and fluids [1]. Moreover, myelin basic
protein has been suggested as a substrate for POP [12].
Recent studies indicate a close association between
inflammation and neurodegeneration in all lesions and
disease stages of MS [13]. MS is associated to immuno-
logical changes elicited by endogenous myelin-associated
antigens such as myelin oligodendrocyte glycoprotein,
proteolipoprotein, and myelin basic protein [14]. Acute
lesions are thought to result when activated T cells,
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the central nervous system and trigger a cascade of
inflammatory events. Widespread axonal degeneration
and brain atrophy appear early in the disease course and
are prominent in progressive forms of MS. During an
acute inflammatory attack, increases in free radicals lead
to mitochondrial damage and decreased ATP production,
which would be expected to inhibit axonal transport,
including the transport of mitochondria [15]. Inflamma-
tion also activates signalling pathways that inhibit axonal
transport.
Recently a direct role for POP as a modulator of the
inflammatory response has been proposed [16]. This
response involves a multistep process during matrix met-
alloproteases (MMPs) mediated collagen degradation,
resulting in formation of the peptide, N-acetylated-pro-
line-glycine-proline (N-α-PGP), a POP product. This
peptide has been described as a neutrophil chemoattrac-
tant and also as a stimulator of superoxide production
[17]. In addition, PGP is a biomarker for chronic obstruc-
tive pulmonary disease (COPD), an inflammatory disor-
der [18]. This study has also shown that POP, in
conjunction with MMPs, is required for production of
PGP. Kamori and collaborators [19], have showed that
POP activity levels are increased in knee joint synovial
membrane of patients with rheumatoid arthritis, a sys-
temic inflammatory disorder.
On the other hand, recent studies have shown that POP
is a mediator of the toxic effect that reactive microglia
cells have in a neural cell culture model. This effect is
reduced by POP inhibitors [20]. The presence of reactive
microglia cells has been observed in Alzheimer's, Parkin-
son's, Pick's and Huntington's diseases, amyotrophic lat-
eral sclerosis, AIDS encephalopathy, and MS [21].
Additionally, microglia are the principal cells that medi-
ate innate immune responses in the CNS.
POP has been found to be responsible for the genera-
tion of the thymosin β-4 derived peptide N-acetyl-seryl-
aspartyl-lysyl-proline (Ac-SDKP, [22]). Ac-SDKP is
involved in inflammatory cell infiltration, perivascular
fibrosis and glomerulosclerosis [23], and in human malig-
nant tumours [24]. We have evidence that β-thymosin is
indeed a physiological substrate of POP in brain [25].
Alterations in plasma POP activity have been found in
several neurological diseases, but to our knowledge, the
possible involvement of this peptidase in MS has never
been studied. POP has implications in several processes
relevant to MS: 1) it has a role in the inflammatory
response through generation of key peptides from degra-
dation of extracellular matrix proteins; 2) it is related to
microglia activation and T cell response; 3) it is involved
in degradation of myelin basic protein; and 4) it has a role
in axonal transport. Based in all these clues, we hypothe-
sised that POP activity would be altered in MS. In this
study, we have analysed the levels of POP activity, and
those of an endogenous POP inhibitor, in a Spanish sam-
ple of clinically diagnosed MS patients. We also analysed
the results in relation to patient age and disability in
search of possible correlations.
Methods
Patients
Eleven patients, 7 females and 4 males, of an average age
of 32 ± 7 years were used in this study. All the patients
had confirmed clinical diagnosis of MS according to the
modified McDonald criteria [26]. Furthermore, all the
subjects were clinically classified as having the relapsing
remitting form of MS according to the criteria described
by Lublin and Reingold [27]. The time of evolution of the
disease from the onset of the dysfunction was between 2
to 156 months (mean 71 ± 60 months), and the Kurtzke
Expanded Disability Status Scale (EDSS) [28] score of the
MS patients ranged from 1.5 to 3.5 at the time when the
samples were taken. All patients were on interferon-β
therapy.
Controls
Age-matched healthy volunteers (8 females and 9 males)
were recruited for this study. None of the controls had a
history of neurological symptoms or of any chronic dis-
ease.
Blood sampling
Blood was collected from controls and patients by veni-
puncture from an antecubital vein. Blood (8.5 ml/tube)
was directly drawn into two evacuated tubes containing
anticoagulants (buffered citrate, EDTA). After collection,
blood specimens were spun at 10,000 × g for 1 minute at
4°C. Supernatant plasma was aliquoted and stored at -
80°C.
Ethical considerations
This study was approved by the Ethical Committee of the
Centro de Investigación Principe Felipe, Valencia, Spain
and followed local and European regulations. All subjects
gave their informed consent for the blood collection.
Partial purification of POP
Prolyl oligopeptidase was purified from porcine brain by
ion exchange chromatography as described before [29].
Enzymatic assay
As repeated cycles of freeze-thawing inactivates POP
[30], all the samples were analysed after only one freezing
cycle. Plasma aliquots (25 μl) were added to each well of a
96-well plate which contained 220 μl 100 mM of sodium
phosphate pH 7.0 and pre-incubated 30 min at 30°C.
Then, 5 μl of the substrate Z-Gly-Pro-amino methyl cou-
marin (Z-GP-AMC, 10 mM, Bachem, Wheil am Rhein,
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measuring the increase of fluorescence released from
amino methyl coumarin (AMC). The measures were
taken every minute over a time course of 90 min at 30°C.
Two enzymes account for the total prolyl endopeptidase
detected in plasma [31]. One is resistant to specific POP
inhibitors and is referred to as Z-Pro-Prolinal (ZPP)-
insensitive prolyl endopeptidase, or ZIP activity. A sec-
ond, POP activity, corresponds to the fraction sensitive to
the inhibitor. Accordingly, we report POP activity as the
difference between the total activity and the fraction
resistant to 50 nM of ZPP (Fig. 1).
POP endogenous inhibitor
For determination of POP endogenous inhibitor in
plasma, purified porcine POP (800 ng) was used in the
fluorescence activity assay described above, with or with-
out pre-incubation with 25 μl of plasma. Endogenous
POP inhibitor level is reported as the percentage of inhi-
bition caused by the plasma, in these conditions, on puri-
fied POP activity. The plasma prolyl endopeptidase
activity contribution was less than 10%, and was sub-
tracted in all cases. All assays were done by triplicate.
Data analysis
All analysis was performed using GraphPad Prism 4 soft-
ware (La Jolla, CA, USA). For comparison between differ-
ent groups, student's unpaired t test and one-way
ANOVA, with Tukey post hoc test, analysis were used.
Differences were considered statistically significant when
a p value was <0.05. Results are expressed as means ±
S.E.M.
Results
Plasma collection conditions affect prolyl endopeptidase 
activity and stability
Important variations in activity and stability of POP due
to preparation and assay conditions have been noticed
before [30]. On the other hand, two different enzymes in
plasma, with prolyl endopeptidase activity, have been
described [31]. Apart from classical POP, the alternative
activity is insensitive to POP-specific inhibitors, and is
called Z-Pro-Prolinal insensitive peptidase or ZIP. This
activity has been attributed to the action of fibrinogen
activated protein α (FAPα) or seprase [32]. On the other
hand, Breen and collaborators [31] have reported that
cation chelators, which are currently used during plasma
preparation, affect POP activity. Our experiments indi-
cate that while neither citrate nor EDTA in the plasma
affected the levels of ZIP activity (Fig. 1A), activity of
POP, or the Z-pro-prolinal sensitive activity level, was
found to be substantially lower in the presence of citrate
(p < 0.05). EDTA-containing plasma seems to have higher
levels of POP (Fig. 1B). To verify the sensitivity to these
Figure 1 Prolyl oligopeptidase activity is sensitive to chelating 
agents but the alternative ZIP activity is not. Prolyl endopeptidase 
activity in plasma from healthy controls collected in the presence of 
citrate (gray bars) or EDTA (white bars). A. Z-Pro-Prolinal insensitive 
prolyl endopeptidase (ZIP). B. POP activity, *, p-value = 0.037. n = 4. C. 
Effect of increasing concentrations of citrate (-Њ-) or EDTA (--) on hu-
man recombinant purified POP activity. Concentrations of 1.8 mg/ml 
EDTA or 3.2 mg/ml citrate (arrows) were used in the experiments 
shown in A. and B.
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of purified POP (Fig. 1C). We observed that both com-
pounds inhibit POP activity. However, at the concentra-
tions found in the plasma samples (1.8 mg/ml EDTA and
3.2 mg/ml citrate), POP activity is practically unaffected
by EDTA while citrate produces an inhibition of nearly
50% (Fig. 1C). Accordingly, only EDTA-containing
plasma was used for further experiments.
POP activity is altered in remitting-relapsing multiple 
sclerosis and it is related to disease disability status
We measured POP activity in plasma of RR-MS patients
and compared this with the activity in control samples
(Fig. 2). Strikingly, we observed an important decrease in
POP activity in RR-MS plasmas relative to controls of
about 60% (p-value < 0,0005; Fig. 2A). Because MS is a
degenerative disease, we considered it relevant to analyze
changes in POP activity as a function of patient age and
disability status. In Fig. 2B we show the POP activity data
from RR-MS patients and controls plotted against age.
While there is a clear inverse correlation of POP activity
with age for healthy subjects (slope -0.037 ± 0.01; Pearson
r = 0,515, p-value < 0.05), in RR-MS patients activity
remains at medium-low to low level in all ages. It is clear
that in the disease state POP activity is already low in
younger subjects and no important changes are observed
with age.
Blood samples analysed were collected from a hetero-
geneous patient population in terms of disability progres-
sion. These disability symptoms ranged from the most
benign and slightly disabling, for some patients, to the
most aggressive and highly disabling for others. This led
us to analyse if changes in POP activity were also related
to degree of disability. The Fig. 3 shows POP activity in
RR-MS patients related to EDSS score. We clearly found
that plasma POP activity decreases with increased dis-
ability status (Fig. 2, slope -0.27 ± 0.08; Pearson r = 0.74;
p-value < 0.05).
POP endogenous inhibitor levels in plasma are increased in 
RR-MS patients
An endogenous POP inhibitor has been reported before
[33] and has been identified as a peptide [34]. This pep-
tide has been proposed as a modulator of POP activity. To
verify whether the decrease in POP activity in diseased
plasma is due to the action of this or of some hitherto
unknown inhibitory factor present in plasma of MS
patients, we measured the effect of whole plasma on the
turnover of in vitro purified human recombinant POP. As
is shown in Fig. 4A, healthy plasma induced a 12% (±2%)
inhibition of POP activity while, under the same condi-
tions, diseased plasma doubled this effect, inhibiting the
peptidase activity 28% (±3) (p-value < 0.0005, healthy vs.
Figure 2 Prolyl oligopeptidase activity in plasma and the varia-
tion with age of healthy subject and RR-MS patients. POP activity 
in plasmas from healthy controls (white bar, n = 17) and RR-MS pa-
tients (gray bar, n = 11) (A.) ***, p-value = 0.0076 t-student unpaired 
test. B. Relationship between POP activity and subject age for both 
healthy controls and RR-MS patients. Correlation for healthy controls, n 
= 17, Pearson r = -0.5153, p-value (two-tailed) = 0.03, R-square = 0.2656.
Figure 3 Prolyl oligopeptidase level and MS disability status. Cor-
relation between plasma POP activity with the EDSS score from RR-MS 
patients; n = 10, Pearson r = -0.74, p-value (two-tailed) = 0.0144, R-
square = 0.5476.
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were responsible for the lower POP activity found in MS
patients, it might be expected that a correlation would
exist between the increase of inhibitory factor and the
decrease of activity. When comparing inhibitory factor
levels against POP activity in plasma we found no corre-
lation, neither for RR-MS patients nor for healthy sub-
jects (Fig. 4B). Furthermore, we also found no correlation
between endogenous inhibitor levels and patient age (not
shown).
Lower POP levels in RR-MS are due to reversible POP 
oxidation
The increase of POP endogenous inhibitor was not suffi-
cient to explain the substantial decrease in POP activity
found in plasma from RR-MS patients. It has been
reported that POP is sensitive to redox conditions and is
inactivated by oxidants [35,36]. On the other hand, it has
been demonstrated that reactive oxygen species (ROS)
are substantially increased in MS [37-40]. Hence, we
tested the effect of DTT (5 mM) on plasma POP activity.
For this purpose, we repeated the POP assay for all sam-
ples but after a 5-min pre-incubation with 5 mM DTT.
We found that DTT had no effect on POP activity in con-
trol samples. However, after pre-incubation with DTT,
plasma from diseased patients showed increased POP
activity comparable to control levels (p-value < 0.005)
(Fig. 5).
Discussion
Many aspects of MS aetiology and pathophysiology are
unresolved, but there is increasing evidence that the
relapsing-remitting phase and the progressive phase of
the disease are caused by two distinct mechanisms. Focal
inflammation is believed to be the cause of relapses,
whereas diffuse axonal degeneration appears to be the
main contributor to progression [41]. The accumulation
of disability in MS is thus caused by neuronal damage at
inflammatory foci and by diffuse axonal degeneration.
Current treatments of MS can reduce the number of
relapses but are ineffective in the progressive phase.
POP is a peptidase which cleaves peptides of less than
30 amino acids from the C-side of an internal proline.
Since POP is the only proline-specific endopeptidase in
humans, and since several proline-containing bioactive
peptides are shorter that 30 amino acids, POP has been
suggested to specifically modulate the levels of these pep-
tides [1]. Circulating POP levels have been found to be
modified in psychiatric [42-47] and mood disorders [31],
and these facts have suggested a relationship between
Figure 5 Effect of DTT on prolyl oligopeptidase levels in plasma 
from healthy and RR-MS patients. POP activity in plasma from 
healthy controls (white bar) and RR-MS patients (gray bar) after plasma 
pre-incubation in the absence, or presence (diagonal pattern), of DTT 
(5 mM). n = 10, p-values, **, 0.0024, ***, 0.0004.
Figure 4 Levels of endogenous prolyl oligopeptidase inhibitor, 
and its relation with prolyl oligopeptidase activity, in plasma 
from healthy and RR-MS patients. A. Inhibitory effect of plasma (25 
μl) from healthy controls (white bar, n = 17) and RR-MS patients (gray 
bar, n = 11) on the activity of pure POP (basal activity 100 nmol/min/
mg of POP), ***, p-value = 0.0002. B. Relationship between plasma POP 
activity, and endogenous POP inhibitor content, expressed as % of in-
hibition of pure POP (data from part A.) in healthy controls (n = 17) and 
RR-MS patients (n = 11). No statistically significant correlation was 
found.
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levels. On the other hand, POP has been found to be
related to inflammatory processes through thymosin [23]
or collagen degradation [16]. Furthermore, POP has been
found to be increased in inflamed tissues [19], and has
been found to be secreted from microglia-like cells upon
activation [20]. Reactive microglia play an important role
in a number of neurodegenerative diseases, including MS
[21]. POP has also been reported to interact with
cytoskeletal elements with relation to secretion in neural
cells [48], suggesting a role in axonal transport. Accord-
ingly, we here hypothesise that POP activity is modified
in plasma from MS patients.
In summary, we have found in this study that levels of
POP activity in plasma from RR-MS patients are substan-
tially reduced compared with healthy controls (Fig. 2A).
Analysing this data, we also find that there is a significant
decrease of POP activity with increasing age in healthy
subjects. However, this age-associated pattern is not
observed for RR-MS patients, where the activity was
already substantially lower at early ages (Fig. 2B). Further-
more, we find that the decrease observed in POP activity
in diseased plasma is more pronounced in cases with
more severe symptoms (Fig. 3). We suggest that the
decline in POP activity is related to the molecular mecha-
nism of the disease, and to its severity. In trying to under-
stand the reasons for the low levels of POP which we
found to prevail in RR-MS plasma, we analysed plasma
looking for inhibitory factors. We found that plasma con-
tained a POP endogenous inhibitor. We observed that
levels of this inhibitor are substantially increased in RR-
MS, probably partially explaining the low activities found
in the disease (Fig 4A). However, we did not find any rela-
tionship between the plasma content of this endogenous
inhibitor, and the low POP activity observed in diseased
plasma (Fig. 4B), which suggests the existence of other
factor(s) contributing to this decline. Measures of oxida-
tive stress in blood and cerebrospinal fluid (CSF) of
patients with MS have consistently found increases in a
number of studies [49,50]. POP is sensitive to the oxida-
tive environment, and it has been reported that oxidation
of specific cysteines in this enzyme arrest activity [35,36].
We observed that addition of DTT to plasma from RR-
MS patients increases POP to control levels (Fig. 5). This
suggests that the higher degree of oxidative stress prevail-
ing in MS inactivates POP.
Conclusions
We report here that RR-MS patients show decreased cir-
culating POP activity, and that this reduction might be
correlated with the higher oxidative environment of
plasma of these patients. Additionally, our data indicate
that the amount of plasma endogenous POP inhibitor is
augmented in this disease, but that this factor is only par-
tially responsible for the decreased POP activities found.
We suggest that low amounts of POP activity in MS
plasma are contributing to symptoms of the disease.
Remarkably, we also found that POP activity is decreased
in old age to levels comparable to those found in MS.
On the other hand, the increases observed in levels of
POP inhibitory factor in diseased plasma is probably not
correlated with increased oxidant levels, since there was
no influence of DTT on inhibitory activity in plasma. The
relevance of this endogenous inhibitor increase is still not
known, and further experimentation is required to
answer this question.
Our study is the first to relate POP to MS and indicates
that most probably there is a change in peptidase homeo-
stasis in the disease. Further work is being conducted in
order to define the proteolytic cascades and the peptides
involved in the changes observed in MS. This would con-
tribute to our understanding of disease mechanisms and
its symptomatology. According to the results reported
here, it can be suggested that levels of plasma POP, and of
POP inhibitory factor, could be used as novel tools for
early MS diagnosis and also as an indicator of disease
severity.
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